Expanding the pharmacy network and strengthening home healthcare and nursing care businesses
First written in FY2016. 17 of 36 entries say "Advanced", first in FY2017-Q1. Latest entry: FY2027-H1.
No other company in this theme has enough history to compare yet.
- FY2027-H1Fewer prescriptions due to pharmacy network reviews and closuresAnnual report
「In this business segment, although we promoted initiatives to become the “primary-care pharmacist and pharmacy” chosen by local residents, the number of prescriptions declined due to the impact of store closures associated with a review of the store network, resulting in difficult conditions. As a result, revenue was ¥9,696 million, down 2.0% year on year, and the operating loss was ¥221 million, compared with an operating loss of ¥89 million in the same period of the previous year.」
The number of prescriptions declined due to a review of the store network and store closures, and the operating loss widened from ¥89 million in the same period of the previous year to ¥221 million. - FY2026-H1Operating loss due to higher personnel expensesAnnual report
「In this business segment, the average revenue per prescription and revenue increased as a result of promoting initiatives to become the “primary-care pharmacist and pharmacy” chosen by local residents. However, operating profit declined due to higher personnel expenses, among other factors. As a result, revenue was ¥9,898 million, up 2.2% year on year, and the operating loss was ¥89 million, compared with operating profit of ¥106 million in the same period of the previous year.」
Although the average revenue per prescription and revenue increased as a result of initiatives for the primary-care pharmacist and pharmacy, higher personnel expenses resulted in a shift to an operating loss. - FY2025-H1Lower profit due to higher personnel expensesAnnual report
「In this business segment, the number of prescriptions increased due to the benefits of expanding the store network through openings in the previous fiscal year and initiatives to become the “primary-care pharmacist and pharmacy” chosen by local residents, among other factors. However, operating profit declined due to higher personnel expenses, among other factors. As a result, revenue was ¥9,682 million, up 2.3% year on year, and operating profit was ¥106 million, down 42.6% year on year.」
The number of prescriptions increased as a result of expanding the store network and initiatives for the “primary-care pharmacist and pharmacy,” but operating profit declined 42.6% year on year due to higher personnel expenses. - FY2024AdvancedAnnual report
「In this business segment, as restraint in seeking medical care eased following the reclassification of COVID-19 to Category 5, the number of prescriptions increased due to the benefits of expanding the store network through new openings and initiatives to become the “primary-care pharmacist and pharmacy” chosen by local residents, among other factors, and performance remained strong. As a result, revenue was ¥19,358 million, up 6.8% year on year, and operating profit was ¥378 million, up 233.5% year on year, due in part to fewer new store openings than in the previous fiscal year and a decrease in the one-time costs associated with store openings.」
Easing restraint in seeking medical care, new store openings, and initiatives for the “primary-care pharmacist and pharmacy” resulted in full-year operating profit of ¥378 million in the pharmacy business, up 233.5% year on year. - FY2024-Q3AdvancedAnnual report
「In this business segment, as restraint in seeking medical care eased following the reclassification of COVID-19 to Category 5, the number of prescriptions increased due to the benefits of expanding the store network through new openings and initiatives to become the “primary-care pharmacist and pharmacy” chosen by local residents, among other factors, and performance remained strong. As a result, revenue was ¥14,385 million, up 7.0% year on year, and operating profit was ¥286 million, up 349.1% year on year, due in part to fewer new store openings than in the same period of the previous year and a decrease in the one-time costs associated with store openings.」
The easing of restraint in seeking medical care, new store openings, and initiatives for the primary-care pharmacist and pharmacy resulted in operating profit increasing 349.1% year on year. - FY2024-Q2AdvancedAnnual report
「As restraint in seeking medical care eased following the reclassification of COVID-19 to Category 5, the number of prescriptions increased due to the benefits of expanding the store network through new openings and initiatives to become the “primary-care pharmacist and pharmacy” chosen by local residents, among other factors, and performance remained strong. As a result, revenue was ¥9,467 million, up 7.5% year on year, and operating profit was ¥185 million, up 1,663.4% year on year, due in part to fewer new store openings than in the same period of the previous year and a decrease in the one-time costs associated with store openings.」
The easing of restraint in seeking medical care, new store openings, and initiatives for the primary-care pharmacist and pharmacy resulted in operating profit increasing 1,663.4% year on year. - FY2024-Q1AdvancedAnnual report
「In this business segment, the number of prescriptions increased and performance remained strong due to the benefits of expanding the store network through new openings and initiatives to become the “primary-care pharmacist and pharmacy” chosen by local residents, among other factors. As a result, revenue was ¥4,610 million, up 6.7% year on year, and operating profit was ¥65 million, compared with an operating loss of ¥67 million in the same period of the previous year.」
The number of prescriptions increased as a result of new store openings and initiatives for the “primary-care pharmacist and pharmacy,” resulting in a shift from an operating loss in the same period of the previous year to operating profit. - FY2023AdvancedAnnual report
「In this business segment, the number of prescriptions increased and performance remained strong due to the benefits of expanding the store network through new openings and initiatives to become the “primary-care pharmacist and pharmacy” chosen by local residents, among other factors. As a result, revenue was ¥18,121 million, up 2.3% year on year, and operating profit was ¥113 million, up 47.2% year on year.」
Expansion of the store network and initiatives for the “primary-care pharmacist and pharmacy” resulted in full-year operating profit of ¥113 million, up 47.2% year on year. - FY2023-Q3RestatedAnnual report
「In this business segment, the number of prescriptions increased due to the benefits of expanding the store network through new openings and initiatives to become the “primary-care pharmacist and pharmacy” chosen by local residents, among other factors. However, conditions were somewhat difficult due to higher SG&A expenses associated with new store openings.」
The number of prescriptions increased as a result of new store openings and initiatives for the “primary-care pharmacist and pharmacy,” while higher SG&A expenses associated with store openings remained a burden. - FY2023-Q2AdvancedAnnual report
「In this business segment, the number of prescriptions increased due to the benefits of expanding the store network through new openings and initiatives to become the “primary-care pharmacist and pharmacy” chosen by local residents, among other factors. However, conditions were somewhat difficult due to higher SG&A expenses associated with new store openings. As a result, revenue was ¥8,805 million, up 0.9% year on year, and operating profit was ¥10 million, down 77.5% year on year.」
The number of prescriptions increased as a result of new store openings and initiatives for the “primary-care pharmacist and pharmacy.” Although operating profit declined year on year, performance improved from an operating loss to operating profit of ¥10 million. - FY2023-Q1Wider operating lossAnnual report
「In this business segment, the number of prescriptions increased due to the benefits of expanding the store network through new openings and initiatives to become the “primary-care pharmacist and pharmacy” chosen by local residents, among other factors. However, conditions were difficult due to the absence of sales of large medical equipment recorded in the same period of the previous year, the effects of revisions to dispensing fees and drug prices, and higher SG&A expenses associated with new store openings. As a result, revenue was ¥4,321 million, down 0.6% year on year, and the operating loss was ¥67 million, compared with an operating loss of ¥11 million in the same period of the previous year.」
Although expansion of the store network and initiatives for the “primary-care pharmacist and pharmacy” continued, the operating loss widened from ¥11 million to ¥67 million due to the absence of large medical equipment sales recorded in the same period of the previous year, among other factors. - FY2022-Q3AdvancedAnnual report
「In this business segment, the number of prescriptions increased due to the benefits of expanding the store network through new openings and initiatives to become the “primary-care pharmacist and pharmacy” chosen by local residents, among other factors, and performance remained solid. As a result, revenue was ¥13,260 million, up 3.0% year on year, and operating profit was ¥83 million, compared with an operating loss of ¥48 million in the same period of the previous year.」
The number of prescriptions increased as a result of new store openings and initiatives for the “primary-care pharmacist and pharmacy,” improving from an operating loss to operating profit of ¥83 million. - FY2022-Q2AdvancedAnnual report
「In this business segment, the number of prescriptions increased due to the benefits of expanding the store network through new openings and initiatives to become the “primary-care pharmacist and pharmacy” chosen by local residents, among other factors, and performance remained solid. As a result, revenue was ¥8,723 million, up 3.2% year on year, and operating profit was ¥46 million, compared with an operating loss of ¥98 million in the same period of the previous year.」
The number of prescriptions increased as a result of expanding the store network and initiatives for the “primary-care pharmacist and pharmacy,” improving from an operating loss to operating profit of ¥46 million. - FY2022-Q1AdvancedAnnual report
「In this business segment, the number of prescriptions increased as a result of initiatives to become the “primary-care pharmacist and pharmacy” chosen by local residents, among other factors. However, conditions were somewhat difficult due to continued restraint in seeking medical care and higher SG&A expenses associated with new store openings. As a result, revenue was ¥4,348 million, up 3.6% year on year, and the operating loss was ¥11 million, compared with an operating loss of ¥117 million in the same period of the previous year.」
The number of prescriptions increased as a result of initiatives for the “primary-care pharmacist and pharmacy,” and the operating loss narrowed from ¥117 million in the same period of the previous year to ¥11 million. - FY2021Swung to an operating loss for the full fiscal yearAnnual report
「In this business segment, although we promoted initiatives to become the “primary-care pharmacist and pharmacy” chosen by local residents, the number of visitors declined as people refrained from seeking medical care, resulting in difficult conditions. As a result, revenue was ¥17,260 million, down 3.5% year on year, and the operating loss was ¥2 million, compared with operating profit of ¥74 million in the previous fiscal year.」
Although initiatives for the “primary-care pharmacist and pharmacy” continued, the decline in visitors due to people refraining from seeking medical care resulted in a full-year shift from operating profit to operating loss. - FY2021-Q3Operating loss continuesAnnual report
「Although the company promoted initiatives to provide a family pharmacist and pharmacy chosen by local residents, performance remained weak as the number of pharmacy visits declined because patients refrained from visiting medical institutions. As a result, net sales were ¥1,287.6 million, down 3.7% year on year, and the company recorded an operating loss of ¥4.8 million, compared with operating profit of ¥0 million in the previous fiscal year.」
Although initiatives to provide a family pharmacist and pharmacy continued, the company remained in a state of having swung from operating profit in the previous fiscal year to an operating loss because fewer patients visited pharmacies due to deferred medical visits. - FY2021-Q2Wider operating lossAnnual report
「Although the company promoted initiatives to provide a family pharmacist and pharmacy chosen by local residents, performance remained weak as the number of pharmacy visits declined because patients refrained from visiting medical institutions. As a result, net sales were ¥845.1 million, down 4.3% year on year, and the company recorded an operating loss of ¥9.8 million, compared with an operating loss of ¥2.6 million in the previous fiscal year.」
Although initiatives to provide a family pharmacist and pharmacy continued, the operating loss widened from ¥2.6 million in the previous fiscal year to ¥9.8 million as fewer patients visited pharmacies due to deferred medical visits. - FY2021-Q1Deterioration in performance due to deferred medical visitsAnnual report
「Although the company promoted initiatives to provide a family pharmacist and pharmacy chosen by local residents, performance remained weak as the number of pharmacy visits declined because patients refrained from visiting medical institutions. As a result, net sales were ¥419.7 million, down 5.1% year on year, and the company recorded an operating loss of ¥11.7 million, compared with an operating loss of ¥1.2 million in the previous fiscal year.」
Although initiatives to provide a family pharmacist and pharmacy continued, net sales declined and the operating loss widened as fewer patients visited pharmacies due to deferred medical visits. - FY2020-Q3AdvancedAnnual report
「The number of prescriptions processed grew as a result of new store openings and strengthened initiatives to provide a family pharmacist and pharmacy chosen by local residents. However, selling, general and administrative expenses increased in association with new store openings. As a result, net sales were ¥1,336.6 million, up 5.0% year on year, and operating profit was ¥0 million, compared with an operating loss of ¥33.1 million in the previous fiscal year.」
Prescriptions processed grew as a result of new store openings and strengthened initiatives to provide a family pharmacist and pharmacy, improving the operating result from an operating loss to zero operating profit. - FY2020-Q2AdvancedAnnual report
「The number of prescriptions processed grew as a result of new store openings and strengthened initiatives to provide a family pharmacist and pharmacy chosen by local residents. However, conditions remained somewhat challenging due to higher selling, general and administrative expenses associated with new store openings. As a result, net sales were ¥882.9 million, up 7.2% year on year, and the company recorded an operating loss of ¥2.6 million, compared with an operating loss of ¥27.9 million in the previous fiscal year.」
Prescriptions processed grew as a result of new store openings and strengthened initiatives to provide a family pharmacist and pharmacy, while the operating loss narrowed from ¥27.9 million in the previous fiscal year to ¥2.6 million. - FY2020-Q1AdvancedAnnual report
「The number of prescriptions processed grew as a result of new store openings and initiatives to provide a family pharmacist and pharmacy chosen by local residents, but conditions remained somewhat challenging as the impact of the previous year's revisions to dispensing fees and drug prices continued. As a result, net sales were ¥442.1 million, up 6.5% year on year, and the company recorded an operating loss of ¥1.2 million, compared with an operating loss of ¥16.9 million in the previous fiscal year.」
Prescriptions processed grew as a result of new store openings and initiatives to provide a family pharmacist and pharmacy, while the operating loss narrowed from ¥16.9 million in the previous fiscal year to ¥1.2 million. - FY2019Operating loss recorded for the full fiscal yearAnnual report
「The number of prescriptions processed grew as a result of new store openings, M&A and strengthened home healthcare initiatives. However, conditions remained challenging due to the impact of revisions to dispensing fees and drug prices and higher selling, general and administrative expenses associated with new store openings. As a result, net sales were ¥1,722.2 million, down 0.3% year on year, and the company recorded an operating loss of ¥27.7 million, compared with operating profit of ¥30.3 million in the previous fiscal year.」
Although the company continued expanding its pharmacy network and strengthening home healthcare, it recorded an operating loss for the full fiscal year due to revisions to dispensing fees and drug prices and store-opening costs. - FY2019-Q3Expansion of operating lossesAnnual report
「The number of prescriptions processed grew as a result of new store openings, M&A and strengthened home healthcare initiatives. However, conditions remained challenging due to the impact of revisions to dispensing fees and drug prices and higher selling, general and administrative expenses associated with new store openings. As a result, net sales were ¥1,272.5 million, down 0.3% year on year, and the company recorded an operating loss of ¥33.1 million, compared with operating profit of ¥22.9 million in the previous fiscal year.」
The expansion of the pharmacy network and home healthcare initiatives increased prescriptions processed, but the operating result deteriorated from operating profit of ¥22.9 million in the previous fiscal year to an operating loss of ¥33.1 million due to revisions to dispensing fees and drug prices and store-opening costs. - FY2019-Q2Continued deterioration in profitabilityAnnual report
「The number of prescriptions processed grew as a result of new store openings, M&A and strengthened home healthcare initiatives. However, conditions remained challenging due to the impact of revisions to dispensing fees and drug prices and higher selling, general and administrative expenses associated with new store openings. As a result, net sales were ¥823.5 million, down 1.9% year on year, and the company recorded an operating loss of ¥27.9 million, compared with operating profit of ¥14.6 million in the previous fiscal year.」
The expansion of the pharmacy network and home healthcare initiatives continued to drive growth in prescriptions processed, but the company swung to an operating loss due to revisions to dispensing fees and drug prices and store-opening costs. - FY2019-Q1Deterioration in profitabilityAnnual report
「The number of prescriptions processed grew as a result of new store openings, M&A and strengthened home healthcare initiatives, but conditions remained challenging due to the impact of revisions to dispensing fees and drug prices. As a result, net sales were ¥415.0 million, down 1.9% year on year, and the company recorded an operating loss of ¥16.9 million, compared with operating profit of ¥8.1 million in the previous fiscal year.」
New openings, M&A and home healthcare initiatives continued to drive growth in prescriptions processed, but the company swung to an operating loss due to the impact of revisions to dispensing fees and drug prices. - FY2018AdvancedAnnual report
「M2メディカル株式会社 was newly acquired in March 2018 and has been included in the scope of consolidation since the end of the current consolidated fiscal year.」
As part of the expansion of the pharmacy network, M2メディカル was acquired in March 2018 and included in consolidation from the fiscal year-end. - FY2018-Q3AdvancedAnnual report
「The number of prescriptions processed grew as a result of the expansion of the pharmacy network through new openings and M&A, while performance was strong due to initiatives in home healthcare and the company's family pharmacist and pharmacy program. As a result, net sales were ¥1,276.5 million, up 9.5% year on year, and operating profit was ¥22.9 million, up 276.5%.」
In addition to expanding the pharmacy network through new openings and M&A, initiatives including home healthcare increased prescriptions processed, resulting in net sales and operating profit exceeding the previous fiscal year. The company also acquired and consolidated 株式会社板東薬品. - FY2018-Q2RestatedAnnual report
「The number of prescriptions processed grew as a result of new store openings, M&A and strengthened home healthcare initiatives, resulting in strong performance.」
The company continues to expand its pharmacy business through new openings, M&A and strengthened home healthcare. - FY2018-Q1AdvancedAnnual report
「The number of prescriptions processed grew as a result of new store openings, M&A and strengthened home healthcare initiatives, resulting in strong performance. Net sales were ¥423.2 million, up 12.1% year on year, and operating profit was ¥8.1 million, up 4,896.5%.」
Prescriptions processed grew as a result of new openings, M&A and strengthened home healthcare, resulting in strong performance with net sales and operating profit exceeding the previous fiscal year. - FY2017RestatedAnnual report
「The number of prescriptions processed grew as a result of new store openings, M&A and strengthened home healthcare initiatives, but conditions remained challenging due to the impact of revisions to dispensing fees and drug prices and higher selling, general and administrative expenses associated with new store openings.」
The company reported growth in prescriptions processed from new openings, M&A and strengthened home healthcare, while challenging conditions continued due to revisions to dispensing fees and drug prices and store-opening costs. - FY2017-Q3RestatedAnnual report
「The number of prescriptions processed grew as a result of new store openings, M&A and strengthened home healthcare initiatives, but conditions remained challenging due to the impact of revisions to dispensing fees and drug prices and higher selling, general and administrative expenses associated with new store openings.」
The company reported growth in prescriptions processed from new openings, M&A and strengthened home healthcare, while challenging conditions continued due to revisions to dispensing fees and drug prices and store-opening costs. - FY2017-Q2AdvancedAnnual report
「AM Pharmacy Co., Ltd. was included in the scope of consolidation from the second quarter of the fiscal year under review after the company newly acquired its shares in July 2016.」
The expansion of the pharmacy network and M&A made concrete progress with the acquisition and consolidation of 株式会社エイエム・ファーマシー in July 2016. - FY2017-Q1AdvancedAnnual report
「The number of prescriptions processed grew as a result of new store openings, M&A and strengthened home healthcare initiatives, but profit margins declined due to the impact of revisions to dispensing fees and drug prices, resulting in challenging conditions.」
The company reported growth in prescriptions processed as a result of new openings, M&A and strengthened home healthcare, while profit margins declined. - FY2016First statedAnnual report
「The number of prescriptions processed grew as the expansion of the pharmacy network through new openings and M&A proved effective, along with strengthened initiatives in home healthcare. Performance was also strong as the company strengthened home-visit care, day-care services and other nursing care businesses.」
New openings, M&A, home healthcare, home-visit care and day-care services are the company's growth drivers.